Teva to sell UK and Ireland Actavis assets in £603m dealStaff Writer | October 5, 2016
Teva will sell assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare, a subsidiary of Intas Pharmaceuticals, for £603 million, subject to final approval from the European Commission.
Pharma The divestment of certain specified assets
The sale will include a portfolio of generic medicines plus a manufacturing plant in Barnstaple, England. Teva retains a number of Actavis non-overlapping generic products plus certain specialty medicines and OTC (over-the-counter) products, which have been added to Teva’s existing operations.
The transaction is expected to close in the next three months. ■